Format

Send to

Choose Destination
Ann Pharmacother. 2004 Nov;38(11):1942-5. Epub 2004 Aug 17.

Sincalide in patients with parenteral nutrition-associated gallbladder disease.

Author information

1
College of Pharmacy, University of Michigan, Ann Arbor, MI, USA.

Abstract

OBJECTIVE:

To review the role of sincalide in treating and preventing parenteral nutrition (PN)-associated gallbladder disease.

DATA SOURCES:

A MEDLINE (1996-March 2004) search was performed using the key terms cholecystokinin, sincalide, parenteral nutrition, cholelithiasis, cholestasis, and sludge.

DATA SYNTHESIS:

Five human studies investigated the safety and efficacy of sincalide in patients with PN-associated gallbladder disease. Sincalide at intravenous doses of 0.04 microg/kg 3 times daily increased bile flow and improved serum bilirubin levels. However, patients with advanced liver disease did not respond to sincalide therapy. Long-term follow-up data on sincalide effects on liver disease progression are not yet available.

CONCLUSIONS:

Sincalide improved the signs of cholestasis. However, its long-term effects in preventing and treating PN-associated gallbladder disease remain unknown and its routine use for this indication cannot be recommended at this time.

PMID:
15316105
DOI:
10.1345/aph.1E153
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center